LCTX Lineage Cell Therapeutics, Inc.
$1.04▲ +0.97%
Healthcare
Other
Volume 1.08M
Avg Volume (10D) 1.43M
Key Metrics & Fundamentals
Market Cap
$263.02M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.88 - 2.09
% vs 50 MA
2.02%
% vs 200 MA
-21.98%
RSI-14
57.1
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.16
Free Cash Flow
-$7.35M
Gross Rev
$1.07M
Gross Profit
$1.07M
EBITDA
-$18.84M
COGS
$0
Operating Exp
$9.99M
Operating Income
-$8.92M
EBIT
-$8.92M
Pretax Income
$1.54M
Net Income
$1.48M
EPS (Diluted)
0.01
Price & Volume History
Loading chart…
Recent News
3 Small Cap Stocks With Strong Revenue Growth And Low Debt
Simply Wall St. · Sep 15, 2026 8:46 PM ET
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Business Wire · Sep 8, 2026 8:00 AM ET
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 8:32 PM ET
Lineage Cell Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 9, 2026 3:04 PM ET
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 7, 2026 8:30 AM ET
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...
GuruFocus.com · Aug 7, 2026 1:12 AM ET
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 6, 2026 5:40 PM ET
Lineage Cell: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 4:42 PM ET
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 6, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LCTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.